Groenland Carline N L, Siemers Adinde H, Dubois Eric A, Gommers Diederik, Heunks Leo, Wils Evert-Jan, Baggen Vivan J M, Endeman Henrik
Department of Intensive Care, Erasmus MC, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands.
Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC, Rotterdam, The Netherlands.
Ann Intensive Care. 2025 Jan 9;15(1):2. doi: 10.1186/s13613-025-01425-3.
Extubation failure is associated with an increased morbidity, emphasizing the need to identify factors to further optimize extubation practices. The role of biomarkers in the prediction of extubation failure is currently limited. The aim of this study was to investigate the prognostic value of cardiac (N-terminal pro-B-type natriuretic peptide (NT-proBNP), High-sensitivity Troponin T (Hs-TnT)) and inflammatory biomarkers (Interleukin-6 (IL-6) and Procalcitonin (PCT)) for extubation failure in patients with COVID-19 Acute Respiratory Distress Syndrome (C-ARDS).
In this single-center retrospective cohort study, patient characteristics and laboratory measurements were extracted from electronic medical records. Patients were eligible for inclusion if they were extubated after mechanical ventilation. The primary endpoint was extubation failure, defined as the need for reintubation or death within the next seven days after extubation, regardless of whether post-extubation respiratory support was used. Uni- and multivariable logistic regression was performed to investigate the association between biomarkers and extubation failure. Biomarkers were log transformed.
Of the 297 patients included, 21.5% experienced extubation failure. In univariable analysis, NT-proBNP (OR 1.24, 95% CI 1.06-1.47), Hs-TnT (OR 1.72, 95% CI 1.37-2.19) and PCT (OR 1.38, 95% CI 1.16-1.65) measured on the day of extubation were significantly associated with extubation failure. After multivariable adjustment for clinical variables (age, duration of mechanical ventilation, SOFA score), Hs-TnT was the only biomarker that was independently associated with extubation failure (adjusted OR 1.38, 95% CI 1.02-1.90). Patients with both elevated Hs-TnT (≥ 14 ng/mL) and elevated PCT (≥ 0.25 ng/mL) carried the highest risk of extubation failure (46%), while in patients with normal Hs-TnT and PCT values, only 13% experienced extubation failure.
Hs-TnT, NT-proBNP and PCT measured on the day of extubation are associated with extubation failure in mechanically ventilated patients with C-ARDS. Since Hs-TnT is the only biomarker that is independently associated with extubation failure, Hs-TnT could offer additional objective measures for assessing readiness for extubation. Future studies should focus on an integrative approach of biomarkers combined with relevant clinical factors to predict extubation failure.
拔管失败与发病率增加相关,这凸显了识别相关因素以进一步优化拔管操作的必要性。生物标志物在预测拔管失败方面的作用目前有限。本研究的目的是探讨心脏生物标志物(N端前脑钠肽(NT-proBNP)、高敏肌钙蛋白T(Hs-TnT))和炎症生物标志物(白细胞介素-6(IL-6)和降钙素原(PCT))对新型冠状病毒肺炎急性呼吸窘迫综合征(C-ARDS)患者拔管失败的预后价值。
在这项单中心回顾性队列研究中,从电子病历中提取患者特征和实验室检测数据。接受机械通气后拔管的患者符合纳入标准。主要终点是拔管失败,定义为拔管后接下来七天内需要再次插管或死亡,无论拔管后是否使用呼吸支持。进行单变量和多变量逻辑回归分析以研究生物标志物与拔管失败之间的关联。对生物标志物进行对数转换。
纳入的297例患者中,21.5%发生了拔管失败。在单变量分析中,拔管当天测得的NT-proBNP(比值比1.24,95%置信区间1.06 - 1.47)、Hs-TnT(比值比1.72,95%置信区间1.37 - 2.19)和PCT(比值比1.38,95%置信区间1.16 - 1.65)与拔管失败显著相关。在对临床变量(年龄、机械通气时间、序贯器官衰竭评估(SOFA)评分)进行多变量调整后,Hs-TnT是唯一与拔管失败独立相关的生物标志物(调整后比值比1.38,95%置信区间1.02 - 1.90)。Hs-TnT升高(≥14 ng/mL)且PCT升高(≥0.25 ng/mL)的患者发生拔管失败的风险最高(46%),而Hs-TnT和PCT值正常的患者中,只有13%发生拔管失败。
拔管当天测得的Hs-TnT、NT-proBNP和PCT与C-ARDS机械通气患者的拔管失败相关。由于Hs-TnT是唯一与拔管失败独立相关的生物标志物,Hs-TnT可为评估拔管准备情况提供额外的客观指标。未来的研究应侧重于将生物标志物与相关临床因素相结合的综合方法来预测拔管失败。